Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, CyberKnife robotic radiosurgery system, proton beam therapy systems, and diagnostic imaging services. It also offers other treatments and diagnostic services through the use of medical equipment comprising electroencephalography for the diagnosis of epilepsy; thermotherapy for pain relief after radiotherapy and chemotherapy; ultrasound therapy for the treatment of cancer; stereotactic radiofrequency ablation for the treatment of Parkinson's disease; and refraction and tonometry for the diagnosis of ophthalmic conditions, as well as CT scanners and ECT scanners for diagnostic imaging. In addition, the company provides clinical support services, including developing treatment protocols for doctors; and organizing joint diagnosis between doctors in its network and clinical research. Further, it offers radiotherapy and diagnostic equipment leasing and management services to hospitals, as well as consulting services; sells medical equipment; and researches and develops medical technology. Additionally, the company establishes the Beijing Proton Medical Center that provides radiotherapy treatment options to cancer patients; and other specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2017, it operated a network of 44 cooperative centers based in 30 hospitals in 29 cities across 18 provinces and administrative regions in China. Concord Medical Services Holdings Limited was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Offices & clinics of medical doctors
Sub-IndustryN/A
SectorMedical
SymbolNYSE:CCM
CUSIPN/A
Phone86-10-5903-6688
Debt
Debt-to-Equity Ratio0.44
Current Ratio1.00
Quick Ratio1.00
Price-To-Earnings
Trailing P/E Ratio-3.70
Forward P/E Ratio53.86
P/E GrowthN/A
Sales & Book Value
Annual Sales$50.87 million
Price / Sales3.21
Cash FlowN/A
Price / CashN/A
Book Value$3.60 per share
Price / Book1.05
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees739
Outstanding Shares43,360,000
Market Cap$178.42
Concord Medical Services (NYSE:CCM) Frequently Asked Questions
What is Concord Medical Services' stock symbol?
Concord Medical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "CCM."
How were Concord Medical Services' earnings last quarter?
Concord Medical Services Hldg Ltd (NYSE:CCM) released its earnings results on Wednesday, August, 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.21 by $0.27. The company earned $18.93 million during the quarter. View Concord Medical Services' Earnings History.
When is Concord Medical Services' next earnings date?
What is the consensus analysts' recommendation for Concord Medical Services?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concord Medical Services in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Concord Medical Services' key competitors?
Some companies that are related to Concord Medical Services include Advanced Medical Solutions (AMS), RadNet (RDNT), Cara Therapeutics (CARA), LeMaitre Vascular (LMAT), Addus Homecare (ADUS), Abeona Therapeutics (ABEO), Aptinyx (APTX), Invacare (IVC), ChemoCentryx (CCXI), Meridian Bioscience (VIVO), Vectura Group (VEGPF), Kura Oncology (KURA), Hanger (HNGR), Dicerna Pharmaceuticals (DRNA) and Dova Pharmaceuticals (DOVA).
Who are Concord Medical Services' key executives?
Concord Medical Services' management team includes the folowing people:
- Dr. Jianyu Yang, Chairman and Chief Exec. Officer (Age 47)
- Mr. Kong Yap Yaw, Chief Financial Officer (Age 54)
- Ms. Xun Liu, Financial Controller
Has Concord Medical Services been receiving favorable news coverage?
Media headlines about CCM stock have been trending somewhat positive on Monday, Accern reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Concord Medical Services earned a media sentiment score of 0.04 on Accern's scale. They also assigned press coverage about the company an impact score of 43.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Concord Medical Services?
Shares of CCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Concord Medical Services' stock price today?
One share of CCM stock can currently be purchased for approximately $3.77.
How big of a company is Concord Medical Services?
Concord Medical Services has a market capitalization of $178.42 million and generates $50.87 million in revenue each year. The company earns $-43,690,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Concord Medical Services employs 739 workers across the globe.
How can I contact Concord Medical Services?
Concord Medical Services' mailing address is 18/F TOWER A GLOBAL TRADE CENTER 36 NORTH THIRD RING ROAD DONGCHENG DISTRICT, BEIJING F4, 100013. The company can be reached via phone at 86-10-5903-6688 or via email at [email protected]
MarketBeat Community Rating for Concord Medical Services (NYSE CCM)
MarketBeat's community ratings are surveys of what our community members think about Concord Medical Services and other stocks. Vote "Outperform" if you believe CCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
